Healthcare DIVE January 28, 2020
Hailey Mensik

Dive Brief:

  • Poor oversight of the 340B Drug Discount Pricing Program and the Medicaid Drug Rebate Program may allow the discounts to be received twice for the same drug, according to a new report from the U.S. Government Accountability Office.
  • CMS does not track or review states’ procedures for preventing duplicate discounts, according to the report. Additionally, procedures that states use to exclude 340B drugs from Medicaid discounts are not always documented or effective at identifying these drugs.
  • The report released Monday also found that states might be forgoing discounts and rebates for all eligible drugs, resulting in increased costs to state and federal governments.

Dive Insight:

The report is likely to add more fuel to the fire...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: GAO, Govt Agencies, Health System / Hospital, Insurance, Market Research, Medicaid, Pharma, Provider, States, Trends
How 3 hospitals are reimagining behavioral crisis care
How Health Systems Can Collaborate on AI Tools
Critical access hospitals face uphill battle: 6 things to know
AdventHealth's plans for new Florida hospital move forward
OSU Wexner CEO's blueprint for improving care in 2025

Share This Article